• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld Asia

BioWorld Asia

Dec. 12, 2018

View Archived Issues

Brii Biosciences forges partnerships with VBI, Vir, Wuxi

HONG KONG – Brii Biosciences has entered into two significant partnerships to expand its pipeline. The first is a license and collaboration agreement with VBI Vaccines Ltd. and Vir Biotechnology Inc. focused on hepatitis B virus (HBV) infection. Brii Bio licensed greater China rights, which includes the Chinese mainland, Hong Kong, Macau and Taiwan, for a recombinant protein-based immunotherapeutic (VBI-2601) from VBI Vaccines in a deal that could be worth up to $129 million plus royalties.  Read More

Revance broadens target on Allergan's back with Fosun deal, phase III aesthetic data

Revance Therapeutics Inc. has never made a secret of its goal to build a better Botox. The Newark, Calif.-based company is making swift progress to reach that target as it prepares to file a BLA for lead program RT-002, an injectable formulation of daxibotulinumtoxinA, in moderate to severe glabellar lines after moving RT-002 into a pivotal phase III to treat cervical dystonia. Read More

More patent lawsuits expected in Japan over biosimilars

TOKYO – Defying the non-litigious nature of Japanese companies, makers of drugs and biosimilars are increasingly willing to file lawsuits to protect patents or clear the way to market biosimilars. Read More

Seagen, Takeda bolster Adcetris' role in treating aggressive blood cancer PTCL

SAN DIEGO – First-line treatment of peripheral T-cell lymphomas (PTCL) with a quartet of drugs substituting Adcetris (brentuximab vedotin) for Oncovin (vincristine) in the decades-old standard of care for the disease, CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), proved superior on both progression-free survival and overall survival, according to full data reported Tuesday by Seattle Genetics Inc. and partner Takeda Pharmaceutical Co. Ltd. Read More

After Zika cure, Tychan accelerates monoclonal antibody for yellow fever

HONG KONG – In just seven months, Singapore-based biotech company Tychan Pte Ltd. has moved its monoclonal antibody, TY-014, from initiation and into clinical development. Read More

Other news to note

Changzhou Qianhong Bio-pharma Co. Ltd., of Changzhou, China, said it started phase two construction of its pharmaceuticals production facility at Changzhou National Hi-tech District involving an investment of ¥1 billion (US$145.8 million). The facility will focus on the research and development of innovative and first-of-its-class-in-China biological drugs.  Read More

Appointments & advancements

Shuwen Biotech Co. Ltd., of Deqing, China, appointed Irina Buhimschi scientific advisor.  Read More

Clinical data for December 4 – 10, 2018

Read More

Regulatory actions for December 4 – 10, 2018

Read More

Conference data: American Society of Hematology (San Diego)

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 4, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 4, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Pill with British pound sign

    Pharma execs speak out: UK pricing rebates scare investors

    BioWorld
    The row between pharma companies and the U.K. government over rebates has intensified, with the Association of the British Pharmaceutical Industry calling up its...
  • Handshake with DNA, molecules

    Regeneron boosts obesity pipeline with Hansoh’s GLP-1/GIP for $2B

    BioWorld
    Regeneron Pharmaceuticals Inc. is adding to its obesity pipeline by in-licensing Hansoh Biomedical Co. Ltd.’s phase III dual glucagon-like peptide 1...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe